Lou Tartaglia
InvestorManaging Partner at Cure Ventures Β· Partner at Third Rock Ventures
Greater Boston
About
Managing Partner and Co-Founder with over 30 years in biotech and venture capital. Previously led 5AM Ventures' company formation initiative, was a Partner at Third Rock Ventures, and was the first employee of Millennium Pharmaceuticals.
Experience
- Cure VenturesManaging Partner and Co-Foundercurrent2021 β present
- 5AM VenturesVenture Partner2018 β 2020Greater Boston
- 5AM VenturesHead of 4:592016 β 2018Greater Boston
- Solstice BiologicsCEO2014 β 2015San Diego/Boston
- Third Rock VenturesPartner2007 β 2014
- Gene LogicGeneral Manager2004 β 2007
- Millennium PharmaceuticalsVP Metabolic Diseases1993 β 2004
- GenentechPostdoc1990 β 1993
Education
- University of California, BerkeleyDoctor of Philosophy (Ph.D.), Biochemistry1985 β 1990
- University at AlbanyBachelor of Science (B.S.), Chemistry1981 β 1985
Skills & more
Biotechnology93Lifesciences36Technology Transfer58Commercialization58Drug Discovery46Venture Capital18Start-ups10Oncology19Medical Devices11Biopharmaceuticals30Clinical Development20R&D11
+12 more
LicensingImmunologyMolecular BiologyCorporate DevelopmentMergersDue DiligenceBiochemistryGenomicsStrategyPharmaceutical IndustryLife SciencesDrug DevelopmentFrom Lou's professional profile.
Same school
Also attended University of California, Berkeley863
Byron DeeterPartner at Bessemer Venture PartnersTrevor OelschigInvestment Team at General CatalystBrendan Bulik-SullivanInvestor at GV (Google Ventures)Glen AndersonPartner at Monta Vista CapitalAnthony LinHead of Intel Capital, Corporate Vice President at Intel CapitalScott ShawChief of Staff at Intel Capital
+ 857 more
Also attended University at Albany37
Christine MurphyInvestor at TRANSFORMATION CAPITALJJ AghaChief Information Security Officer & SVP, IT at Asymmetric Capital PartnersIsabella PiassiInvestor Success at Astella InvestimentosSteven FreidmutterAdvisor at Chloe CapitalDarius AskaripourManaging Partner at Varys CapitalJay FreebergChief Financial Officer at Oncology Ventures
+ 31 more
Shared employers
Also worked at Third Rock Ventures81
Lisa PurcellInvestor at Third Rock VenturesPaul MeloneInvestor at Third Rock VenturesLee VeneziaInvestor at Third Rock VenturesKevin MunnellyInvestor at Third Rock VenturesAmanda ChanInvestor at Third Rock VenturesJigar RaythathaInvestor at Third Rock Ventures
+ 75 more
Also worked at Gene Logic1
Also worked at Millennium Pharmaceuticals25
Kevin MunnellyInvestor at Third Rock VenturesJohn KeiltyVenture Partner at Third Rock VenturesKevin GillisPartner and Chief Operating Officer at Third Rock VenturesKevin StarrInvestor at Third Rock VenturesNeil ExterRetired Partner at Third Rock VenturesRobert TepperPartner and co-founder of Third Rock Ventures
+ 19 more
Also worked at Genentech89
David SchenkeinInvestor at GV (Google Ventures)Karthik ArdhanareeswaranInvestor at GV (Google Ventures)Marco PrunottoInvestor at MedicxiLogan HilleLife Sciences Analyst at CincyTechJosephine ChenInvestor at Sequoia CapitalAbbie CelnikerInvestor at Third Rock Ventures
+ 83 more
Deals Β· 1
Crosslink TherapeuticsBoard seat
via Cure Ventures Β· filed May 2025 Β· $8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Cure Ventures
Albert J. Robichaud
Partner at Cure Ventures
Annie Mitsak
Partner at Cure Ventures
Bill Amsbaugh
CTO and Partner at Cure Ventures
Courtney Turner
Director of Finance at Cure Ventures
David Fallace
Managing Partner at Cure Ventures
Dr. Michael Aberman
Investor at Cure Ventures
Dr. Milenko Cicmil
Investor at Cure Ventures
Drew King
CFO and Partner at Cure Ventures


.jpeg)































